



Vicore announces changes in management team

Gothenburg, November 3, 2020 - Vicore Pharma Holding AB (publ), a pharmaceutical company dedicated to developing innovative medicines for rare lung disorders, today announces changes to the management team.

The management team in Vicore will now consist of the following persons:

- Carl-Johan Dalsgaard, CEO
- Hans Jeppsson, CFO
- Rohit Batta, CMO
- Johan Raud, CSO
- Elin Rosendahl, VP Clinical Development (assumes on November 16)
- Ola Camber, Head of Pharmaceutical R&D
- Nina Carlén, Chief Administrative Officer
- Johanna Gräns, Preclinical Development

“As the development of Vicore’s program progresses, we continuously review the composition of the management team. It is key that we efficiently run our projects in order to achieve the company’s goals and as part of that we are now making changes to the management team.” says Carl-Johan Dalsgaard, CEO.

For further information, please contact:

Carl-Johan Dalsgaard, CEO, tel: +46 70 975 98 63, carl-johan.dalsgaard@vicorepharma.com

This information was submitted for publication on November 3, 2020, at 13:00 CET

About Vicore Pharma Holding AB (publ)

Vicore is a rare disease pharmaceutical company focused on rare lung disorders and related indications. The company currently has three drug development programs, VP01, VP02 and VP03.

VP01 aims to develop the substance C21 for the treatment of idiopathic pulmonary fibrosis (“IPF”), pulmonary fibrosis in systemic sclerosis (“SSc”) and COVID-19. VP02 is based on a new formulation and delivery route of an existing immunomodulatory compound (an “IMiD”). VP02 focuses on the underlying disease and the severe cough associated with IPF. VP01 and VP02 are also being actively evaluated for other indications within the field of interstitial lung diseases which have a significant unmet need. VP03 includes follow-up molecules to VP01.

The company's shares (VICO) are listed on Nasdaq Stockholm's main market. For more information, see www.vicorepharma.com.